Selectively targeting PARP2, either genetically or pharmacologically, to block its interaction with FOXA1 can weaken AR‐mediated gene expression and inhibit the growth of AR‐positive PCa cells. This evidence concerns the gene PARP2 and posterior cortical atrophy.